Cutaneous T-cell Lymphoma Market

1
(No Transcript)
2
Cutaneous T-cell Lymphoma (CTCL)
Cutaneous T-Cell Lymphoma is a group of lympho
-proliferative disorders characterized by
localization of neoplastic T lymphocytes to the
skin. Collectively, CTCL is classified as a type
of non-Hodgkin lymphoma (NHL).
Cutaneous T-cell lymphomas are common types of
skin lymphoma. More than three out of every four
skin lymphomas diagnosed are CTCLs. They often
appear as eczema-like skin rashes and can affect
widespread parts of the body.
There are different subtypes of CTCL. Most are
slow growing, but some can be fast growing. The
most common types of CTCL are Mycosis Fungoides
and Sezary Syndrome.
The men accounts for over 53 of the total cases
of CTCL. The occurrence of CTCL in men had been
higher than in women.

• DelveInsight 2019 All rights reserved

3
CTCL Epidemiology
The higher Cutaneous T-cell Lymphoma incident
cases was 3312 in 2017 in the United States,
followed by EU5 and Japan.
Cutaneous T-cell Lymphoma total incident
population in the seven major markets (7MM) was
estimated to be 8557 cases in 2017.
CTCL prevalence
CTCL PREVALENCE
CTCL prevalence
UK had the highest CTCL incident population
followed by Germany in 2017 whereas Spain had the
lowest incident population. Japan had 1276
Cutaneous T-Cell Lymphoma cases.
CTCL PREVALENCE
There were 1290 early stage and 664 late-stage
Cutaneous T-cell Lymphoma patients in the United
States in 2017.

• DelveInsight 2019 All rights reserved

4
Cutaneous T-cell Lymphoma Market
There are different therapies available for CTCL
treatment, but some of the therapies lead to
adverse events. Bexarotene is an oral retinoid
therapy that is effective for the treatment of
early- and advanced- stage CTCL.
Cutaneous T-Cell Lymphoma market size is
estimated to be USD 703.68 million in 2017 in the
seven major markets (7MM).
The United States accounted for the largest CTCL
market size. Among the EU5 countries, the UK had
the highest market size in 2017, while Spain had
the lowest CTCL market size.
Early stage therapies are topical, including
corticosteroids, retinoids, imiquimod (Aldara),
ultraviolet A irradiation (PUVA), and total skin
electron beam therapy. Systemic therapies are
introduced in the advanced stages where the
disease is widespread and/or resistant to topical
treatment.
Research is undergoing to develop targeted and
more specific therapies for CTCL treatment.
Antifolate inhibitors, agents are currently being
evaluated in patients.
7MM- USA, EU-5(Germany, Spain, Italy, France
and UK), Japan

• DelveInsight 2019 All rights reserved

5
CTCL Emerging Drugs and Companies
01
Drug- SGX301 Company- Soligenix
02
Drug- Quisinostat Company- Janssen
03
Drug- Remetinostat Company- Medivir AB
04
Drug- Resminostat Company- 4SC AG

• DelveInsight 2019 All rights reserved

6
Complete Information
For complete information on
Cutaneous T-cell Lymphoma Market Insights,
Epidemiology Market Forecast-2028 please
click the link below
CLICK HERE
OR
Write Us At 
info_at_delveinsight.com

• DelveInsight 2019 All rights reserved

7
About DelveInsight
1
2
3

• DelveInsight 2019 All rights reserved

8
Services by DelveInsight
PharmDelve
Forecasting
Opportunity Assessment
Consulting
Report Store
Market Intelligence
Competitive Analysis
Pipeline

• DelveInsight 2019 All rights reserved

9
Contact Us
info_at_delveinsight.com
91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

• DelveInsight 2019 All rights reserved

10
Pompe Disease
9